Patent · US Active

Galactoside inhibitor of galectins

US11939349B2 · kind B2 · utility

0Cited by

2References

16Claims

0Family size

Assignee

GALECTO BIOTECH AB · DK

Inventors

Fredrik Zetterberg · Copenhagen, DK
Kristoffer PETERSON · Lund, SE
Karl Jansson · Dalby, SE

Key dates

Filing date	Jul 20, 2022
Grant date	Mar 26, 2024
Priority date	—
Expiry date	Jul 20, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H19/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.